GCS secures 10 million euros in financing

GCS (German Cannabis Standard) has closed a financing round of 10 million euros. The round is based on a company valuation of 60 million euros and, according to the company, is the largest cannabis investment in Europe in 2025. A significant share of the investment comes from a German family office, which is also providing around 21,000 square meters of production space in Solar Valley Bitterfeld-Wolfen. One of the three largest GMP-compliant production facilities for medicinal cannabis in Germany is being built there. Construction of the plant has already started.

We did not start as a first mover, but we want to set standards as a best mover. The financing turns our vision into a mission.

Dogan Küncekli, co-founder of GCS

Vertically integrated business model

GCS pursues a holistic approach and is developing a fully integrated ecosystem, from research and cultivation to digital platforms and patient care in pharmacies. The value chain is divided into three central areas:

GCS Cultivation

The new production facility in Bitterfeld-Wolfen will be built in accordance with GMP standards and certified by the Federal Institute for Drugs and Medical Devices (BfArM). In addition to its own expertise, GCS relies on partners in the field of plant construction and cannabis production.

GCS Technology

The technology ecosystem comprises several platforms:

• Blossom Health (B2C/telemedicine): Patients receive digital access to medicinal cannabis via medical consultations and e-prescriptions, which are transmitted directly to pharmacies.
• Cannaflow (B2B infrastructure & ERP): This platform digitizes the ordering process between pharmacies, wholesalers and telemedicine providers. It integrates the online store, prescription management, payment processing and logistics.
• Cannabiosan (pharmacy purchasing group): By pooling demand, pharmacies should receive better conditions. Smaller locations in rural regions in particular benefit from easier access.

Cannaflow is the industry's digital hub. Blütezeit Health also shows that telemedicine can be legally compliant and user-friendly.

Henrik Willen, co-founder of Cannaflow and Blütezeit Health

Market development and regulation

Since the Medical Cannabis Act (MedCanG) came into force in April 2024, the German market has opened up significantly. The removal of cannabis from the Narcotics Act, the introduction of the e-prescription as standard and the abolition of cultivation quotas create new planning security. For investors, this means attractive framework conditions and growth prospects.

GCS was founded in Berlin and sees itself as a cannabis tech company with a focus on medical cannabis. The business model combines a GMP-compliant cultivation facility "Made in Germany" with digital platforms in the areas of telemedicine, pharmacy purchasing syndicate and B2B ERP systems. GCS thus covers the entire chain from production to dispensing in pharmacies.